Novel Therapies

In May 2019, ACCC and SITC hosted a by-invitation Joint Immuno-Oncology Policy Summit in Washington, D.C. The interdisciplinary discussion focused on next steps in advancing immunotherapy for cancer with a focus on three areas: telehealth, CAR T implications, and care coordination and workforce issues. In this video, summit participants Sarah Murawski, MPAS, PA-C, Hematology/Oncology, Stem Cell Transplant, Cellular Therapy Nocturnist, Vanderbilt Ingram Cancer Center, and Robert Richards, MBA, Administrative Director, Cell Therapy and Transplant, Penn Medicine, UPenn Health System, talk about the future of CAR-T therapy, the need for adequate reimbursement for CAR T, and the potential role telehealth may play in expanding access to this promising new therapy.


The Latest Resources

  • COVID-19 and Patients Receiving Anticancer Immunotherapy
    COVID-19 and Patients Receiving Anticancer Immunotherapy
    By Ryan M. Weight, DO, MS

    SARS-CoV-2 and the resulting respiratory tract infection COVID-19 has upended our society and forcefully changed the way we care for patients. Since the emergence of the virus in early 2020, there have been questions surrounding the risk posed to patients with a cancer diagnosis and the safety of anticancer therapies. 

  • [Publication] Immuno-Oncology in 2020: What We’ve Learned and What Lies Ahead
    In this newly published IO Whitepaper, we take a forward look at how the ACCC IO Institute meets the needs of the evolving multidisciplinary cancer care team and other interdisciplinary providers who may be involved in caring for patients treated with immunotherapies for cancer.
  • The Oncology Pharmacist's Role in IO Delivery
    By Sarah Hudson-DiSalle, PharmD, RPh

    Are you leveraging the assets of your oncology pharmacists in delivery of immunotherapy for cancer? Oncology pharmacists multidisciplinary team members who help bridge the gap between science and real-world medical practice. Sarah Hudson-DiSalle, PharmD, RPh, describes how your IO program can make the best use of the oncology pharmacist's diverse skillset.  

  • Virtual Navigation to Clinical Trials
    By Jennifer C. King, PhD

    In the current oncology clinical trials landscape, many barriers remain to clinical trial enrollment that affect both the oncologist and the patient. Among these are trial locations, strict eligibility requirements, insufficient resources to support appropriate clinical trial education and screening, as well as patient and provider attitudes about trials.

From Oncology Issues

On-Demand Webinars

  • Learn how the microbiome could potentially be used to predict and enhance response to I-O therapy and to recognize patients who could be at risk for developing immune-related adverse events.